1. Riemann L, Boger L, Dahl C, Gemoll T, et al.
   Circulating markers of organ damage associate with COPD in people with HIV: an exploratory proteomic analysis.
   AIDS 2026.
   


2. Parczewski M, Zazzi M, Mielczak K, Bohm M, et al.
   Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.
   AIDS 2026.
   


3. Cabello-Ubeda A, Riggs PK, Honerkamp-Smith G, Wells A, et al.
   Sex-modulated associations between cytomegalovirus cell-associated DNA and cognition in people with HIV on ART.
   AIDS 2026.
   


4. Berenguer J, Ryan P, Ramos-Ruperto L, Martin-Carbonero L, et al.
   Clinical phenotypes and incidence of acute or recent hepatitis C virus infection and bacterial sexually transmitted infections among MSM with HIV.
   AIDS 2026.
   


5. Filip I.
   Cardiovascular risk prediction in people with HIV: looking beyond low-density lipoprotein cholesterol.
   AIDS 2026.
   


6. Chiosi JJ, Freedberg KA.
   Long-acting injectable antiretroviral therapy for people with HIV and adherence challenges to oral medications: From trials to implementation.
   Clin Infect Dis 2026.
   


7. Chen NY, Chen CP, Lin YC, Cheng SH, et al.
   Direct Initiation of Long-Acting Cabotegravir Plus Rilpivirine in People with HIV and Suboptimal Virologic Suppression: A Randomized Trial.
   Clin Infect Dis 2026.
   


8. Havens JP, O'Neill J, Kubat M, Davis JM, et al.
   Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience.
   Clin Infect Dis 2026.
   


9. McKenna L, Frick M, Alarcon-Guizado VA, Davies GR, et al.
   When are Uncontrolled Trials in TB Scientifically and Ethically Justified: Borrowing Wisdom From Early AIDS Clinical Trials.
   Clin Infect Dis 2026;83:e399-e403.
   


10. Adeojo LW, Pauls C, Swaim D, Kumar P, et al.
    Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Rivaroxaban with Cobicistat or Darunavir/Cobicistat in Healthy Participants.
    J Acquir Immune Defic Syndr 2026.
    


11. Duarte MJ, Tien PC, Kuniholm MH, Ma Y, et al.
    PREVALENCE AND SEVERITY OF STEATOTIC LIVER DISEASE IN WOMEN WITH AND WITHOUT HIV.
    J Acquir Immune Defic Syndr 2026.
    


12. Jayadevappa R, Morales K, Hanumali R, Metzger D, et al.
    Association between retention in HIV care, psychiatric comorbidities, and outcomes in veterans with HIV.
    J Acquir Immune Defic Syndr 2026.
    


13. Beer L, Crim SM, Tie Y, O'Shea J, et al.
    Prescription of Long-Acting Antiretroviral Therapy Among U.S. Adults with HIV.
    J Acquir Immune Defic Syndr 2026.
    


14. Velloza J, Adler A, Chakravarty D, Glidden DV, et al.
    Associations between self-reported PrEP use and short and long-term pharmacologic metrics of PrEP adherence among Kenyan women.
    J Acquir Immune Defic Syndr 2026.
    


15. Wang Y, Logie CH, Hasham A, Mackay KI, et al.
    Trends in HIV prevention outcomes among Northern and Indigenous adolescents: A repeated cross-sectional study of arts-based sexual health workshops in the Northwest Territories, Canada.
    J Acquir Immune Defic Syndr 2026.
    


16. Moyle G, Radtchenko J, Gruber J, Dunbar M, et al.
    Weight trajectories in virally suppressed people with HIV compared to matched people without HIV, and predictors of weight gain: a 3-year cohort study from the US TRIO Healthcare Network.
    J Acquir Immune Defic Syndr 2026.
    


17. Springer SA, Di Paola A, Kuo I, Knight K, et al.
    Long-acting Injectable Pre-Exposure Prophylaxis Preference for Persons Who Use Drugs and are Involved with the Criminal Legal System.
    J Acquir Immune Defic Syndr 2026.
    


18. Logie CH, Admassu Z, Okumu M, MacKenzie F, et al.
    Longitudinal associations between condom use self-efficacy trajectories, HIV-related stigma, and HIV prevention engagement among refugee youth in Kampala, Uganda.
    J Acquir Immune Defic Syndr 2026.
    


19. Bauermeister JA, Choi SK, Lin W, Cheshure A, et al.
    A Prospective, Youth-Led Mystery Shopper Assessment of Six Ending the HIV Epidemic Jurisdictions in Florida.
    J Acquir Immune Defic Syndr 2026.
    


20. Lujintanon S, Lesko CR, Haw NJL, Hickey MD, et al.
    Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024.
    J Acquir Immune Defic Syndr 2026.
    


21. Kjaergaard VS, Ledergerber B, Bannister W, Cortez Cardoso Penha R, et al.
    Factors Associated with Persistently Increased IL-6 Levels in People with HIV.
    J Infect Dis 2026.
    


22. Crain CR, Gaiha GD, Gandhi RT.
    Buying Time: T cells and Delayed HIV Rebound After Treatment Interruption.
    J Infect Dis 2026.
    


23. Andersen AB, Juhl AK, Gunst JD, Rasmussen TA, et al.
    Functional T Cell Responses Are Associated With Prolonged HIV Control After Treatment Interruption.
    J Infect Dis 2026.
    


24. Edgar JE, Parker HR, Thobakgale C, Adland E, et al.
    Immune control of HIV viraemia in early paediatric infection is associated with induction of HIV-specific CD8+ T-cell activity following multiple treatment interruptions.
    J Infect Dis 2026.
    


25. Gao J, Ma M, Zhang Y, Wang X, et al.
    Comparative Analysis of NAT, TRFIA, and ELISA for Screening Blood-Borne Pathogens in Preoperative and Pre-Transfusion Patients.
    J Med Virol 2026;98:e71125.
    


26. Hara Y, Kitamura H, Matsuda K, Fujisaki C, et al.
    Identification of a Novel Small Molecule Facilitating HIV Elimination by the "Shock-And-Kill" Approach.
    J Med Virol 2026;98:e71131.
    


27. Kumar M, Bhowmik R, Kumar S, Topno RK, et al.
    Immunopathogenesis of TB-HIV Co-Infection: Mechanisms of Dual Immune Suppression and Viral-Bacterial Synergy.
    Virology 2026;624:111054.
    

Display articles in

• Abstract format